BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 35170548)

  • 21. High
    Xie L; Dang Y; Guo J; Sun X; Xie T; Zhang L; Yan Z; Amin H; Guo X
    Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634629
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
    Liu B; Chen Y; Yang J
    Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ginsenosides, potential TMPRSS2 inhibitors, a trade-off between the therapeutic combination for anti-PD-1 immunotherapy and the treatment of COVID-19 infection of LUAD patients.
    Meng M; Gao R; Liu Z; Liu F; Du S; Song Y; He J
    Front Pharmacol; 2023; 14():1085509. PubMed ID: 36992839
    [No Abstract]   [Full Text] [Related]  

  • 24. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
    Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
    BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased GOLM1 Expression Independently Predicts Unfavorable Overall Survival and Recurrence-Free Survival in Lung Adenocarcinoma.
    Liu X; Chen L; Zhang T
    Cancer Control; 2018; 25(1):1073274818778001. PubMed ID: 29843532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients.
    Wang W; Liu H; Li G
    Front Endocrinol (Lausanne); 2022; 13():947443. PubMed ID: 36105402
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Network module function enrichment analysis of lung squamous cell carcinoma and lung adenocarcinoma.
    Li P; Yuan H; Kuang X; Zhang T; Ma L
    Medicine (Baltimore); 2022 Nov; 101(47):e31798. PubMed ID: 36451444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
    Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
    Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.
    Li L; Liu YD; Zhan YT; Zhu YH; Li Y; Xie D; Guan XY
    Thorac Cancer; 2018 Jul; 9(7):775-784. PubMed ID: 29722145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systematic analysis of IGF2BP family members in non-small-cell lung cancer.
    Gong L; Liu Q; Jia M; Sun X
    Hum Genomics; 2024 Jun; 18(1):63. PubMed ID: 38867248
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Zhang W; Li T; Hu B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and Clinical Significance of SARS-CoV-2 Human Targets in Neoplastic and Non-Neoplastic Lung Tissues.
    Subbarayan K; Ulagappan K; Wickenhauser C; Seliger B
    Curr Cancer Drug Targets; 2021 Jul; 21(5):428-442. PubMed ID: 33292131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The increased expression and aberrant methylation of SHC1 in non-small cell lung cancer: Integrative analysis of clinical and bioinformatics databases.
    Liang Y; Lei Y; Du M; Liang M; Liu Z; Li X; Gao Y
    J Cell Mol Med; 2021 Jul; 25(14):7039-7051. PubMed ID: 34117717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Smoking is Associated with Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Progression through Inducing Distinguishing lncRNA Alterations in Different Genders.
    Liu B; Liu Y; Zou J; Zou M; Cheng Z
    Anticancer Agents Med Chem; 2022; 22(8):1541-1550. PubMed ID: 34315392
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Hu S; Hu Z; Qin J; Lin C; Jiang X
    Aging (Albany NY); 2021 Jun; 13(12):15770-15784. PubMed ID: 34168096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Zengin T; Önal-Süzek T
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
    Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
    Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Hou L; Li Y; Wang Y; Xu D; Cui H; Xu X; Cong Y; Yu C
    Dis Markers; 2018; 2018():4108919. PubMed ID: 30420903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of diagnostic DNA methylation biomarkers specific for early-stage lung adenocarcinoma.
    Cai Q; Zhang P; He B; Zhao Z; Zhang Y; Peng X; Xie H; Wang X
    Cancer Genet; 2020 Aug; 246-247():1-11. PubMed ID: 32805686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
    Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
    PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.